Author

Osamu Ishimoto

Observed names: O Ishimoto, O. Ishimoto, OSAMU ISHIMOTO, 石本, 修

Observed institutions: Tokyo Medical and Dental University, Hirosaki University, Tohoku University, Hokkaido University, Tohoku University Hospital, Miyagi Prefectural Hospital Organization, Sapporo City General Hospital, Sendai Kousei Hospital, Institute of Development, Aging and Cancer, Tohoku University, Niigata University

OpenAlex ID: A5003433296

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

2017 · Toshiaki Takahashi, Takeharu Yamanaka, et al. · The Lancet Oncology · 561

Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402

2008 · Akira Inoue, Shunichi Sugawara, et al. · Journal of Clinical Oncology · 235

Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.

2002 · Osamu Ishimoto, Chikashi Kawahara, et al. · PubMed · 176

Granulocyte-Macrophage Colony–Stimulating Factor and Lung Immunity in Pulmonary Alveolar Proteinosis

2005 · Ryushi Tazawa, Emi Hamano, et al. · American Journal of Respiratory and Critical Care Medicine · 121

Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial.

2014 · Takashi Seto, Toshiaki Takahashi, et al. · Journal of Clinical Oncology · 52

High Level of Vascular Endothelial Growth Factor in Hemorrhagic Pleural Effusion of Cancer

2002 · Osamu Ishimoto, Yasuo Saijo, et al. · Oncology · 49

A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405

2009 · A. Inoue, O. Ishimoto, et al. · Annals of Oncology · 37

PDF

Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study

2018 · Ryo Ko, Takehito Shukuya, et al. · The Oncologist · 31

Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601

2013 · Shunichi Sugawara, Makoto Maemondo, et al. · Lung Cancer · 27

A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer

2006 · Akira Inoue, Kazuhiro Usui, et al. · Lung Cancer · 27

Mutation and Expression of the p51 Gene in Human Lung Cancer

1999 · Masachika Tani, Kimihiro Shimizu, et al. · Neoplasia · 25

PDF

Randomized Phase II Trial Comparing Carboplatin Plus Weekly Paclitaxel and Docetaxel Alone in Elderly Patients With Advanced Non-Small Cell Lung Cancer: North Japan Lung Cancer Group Trial 0801

2014 · Makoto Maemondo, Akira Inoue, et al. · The Oncologist · 20

PDF

A phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703

2012 · Nobumichi Matsubara, Makoto Maemondo, et al. · Respiratory Investigation · 13

Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs

2018 · SATOSHI WATANABE, OU YAMAGUCHI, et al. · Anticancer Research · 10

PDF

A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903)

2014 · Yoshifumi Matsumoto, Makoto Maemondo, et al. · Lung Cancer · 9

Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer

2009 · Osamu Ishimoto, Takashi Ishida, et al. · International Journal of Clinical Oncology · 9

[Prediction of survival of terminally ill cancer patients--a prospective study].

1998 · T Morita, J Tsunoda, et al. · PubMed · 9

Phase II Study of Carboplatin Combined with Biweekly Docetaxel for Advanced Non-small Cell Lung Cancer

2006 · Osamu Ishimoto, Shunichi Sugawara, et al. · Journal of Thoracic Oncology · 7

PDF

Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study

2022 · Tomoyasu Mimori, Takehito Shukuya, et al. · Cancers · 6

PDF

[Accuracy of clinical prediction of survival for terminally ill cancer patients].

1999 · T Morita, J Tsunoda, et al. · PubMed · 5

A phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC)

2005 · K. Usui, A. Inoue, et al. · Journal of Clinical Oncology · 4

Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study

2015 · Osamu Ishimoto, Shunichi Sugawara, et al. · Respiratory Investigation · 3

Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802

2014 · Yosuke Kawashima, Akira Inoue, et al. · Respiratory Investigation · 3

[Bronchial artery embolization can be effective for primary racemose hemangioma].

2003 · Osamu Ishimoto, Nobuyuki Sato, et al. · PubMed · 3

A phase II study of erlotinib monotherpay in patients with previously treated advanced non-small cell lung cancer (NSCLC) without EGFR gene mutation who have never/light smoking history: NEJ006/TCOG0903.

2012 · Yoshiki Ishii, Makoto Maemondo, et al. · Journal of Clinical Oncology · 2

Works count: 48

Citation count: 1,455

H-index: 13

I10-index: 14